Sökning: WFRF:(Amu Sylvie) >
Impact of short-ter...
Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis.
-
- Jin, Tao, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
-
- Bokarewa, Maria, 1963 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
-
Amu, Sylvie, 1978 (författare)
-
visa fler...
-
- Tarkowski, Andrej, 1951 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
-
visa färre...
-
(creator_code:org_t)
- 2009
- 2009
- Engelska.
-
Ingår i: Clinical and experimental rheumatology. - 0392-856X. ; 27:3, s. 491-4
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- BACKGROUND: Imbalance of haemostasis in patients with rheumatoid arthritis (RA) contributes to future risk of cardiovascular diseases (CVD). Prothrombotic molecules, e.g. fibrinogen, D-dimer, and tPA are elevated in plasma of RA patients, being associated to CVD. There is no imformation about the influence of biological drugs, e.g. anti-CD20 and tumor necrosis factor (TNF) antibodies on these prothrombotic molecules. OBJECTIVE: To assess whether anti-TNF and anti-CD20 therapies modify the profiles of cardiovascular risk factors in patients with RA. METHODS: The expression of prothrombotic molecules in plasma was investigated in 10 RA patients before and after treatment with TNF-alpha antibodies and in another 12 RA patients before and after anti-CD20 treatment. RESULTS: Both anti-TNF and anti-CD20 infusions gave rise to clear clinical improvement. However, only anti-CD20 infusion significantly (p=0.05) reduced concentration of fibrinogen (p=0.05), D-dimer (p<0.001), as well as tPA levels (p<0.01). In contrast, in TNF antibody treated patients only tPA levels were significantly decreased following the treatment (p<0.05). CONCLUSIONS: Infusion of CD20 antibodies to the patients with active RA led to a clearly reduced plasma levels of predictors of CVD indicating that this treatment, apart from its anti-inflammatory properties, may reduce the risk for future CVD in RA.
Nyckelord
- Adult
- Aged
- Antibodies
- therapeutic use
- Antibodies
- Monoclonal
- therapeutic use
- Antigens
- CD20
- immunology
- Antirheumatic Agents
- therapeutic use
- Arthritis
- Rheumatoid
- blood
- drug therapy
- C-Reactive Protein
- metabolism
- Cardiovascular Diseases
- Dose-Response Relationship
- Drug
- Female
- Fibrin Fibrinogen Degradation Products
- metabolism
- Fibrinogen
- metabolism
- Humans
- Male
- Middle Aged
- Plasminogen Activator Inhibitor 1
- blood
- Risk Factors
- Tissue Plasminogen Activator
- blood
- Tumor Necrosis Factor-alpha
- antagonists & inhibitors
- immunology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas